554 related articles for article (PubMed ID: 9258460)
21. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
22. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
23. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
24. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution and scintigraphic studies of 153Sm-labeled anti-CEA monoclonal antibody for radioimmunoscintigraphy and radioimmunotherapy.
Fani M; Xanthopoulos S; Archimandritis SC; Stratis N; Bouziotis P; Loudos G; Varvarigou AD
Anticancer Res; 2003; 23(3A):2195-9. PubMed ID: 12894597
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
[TBL] [Abstract][Full Text] [Related]
27. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
30. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
31. Preclinical analysis of intraperitoneal administration of 111In-labeled human tumor reactive monoclonal IgM AC6C3-2B12.
Quadri SM; Malik AB; Tang XZ; Patenia R; Freedman RS; Vriesendorp HM
Cancer Res; 1995 Dec; 55(23 Suppl):5736s-5742s. PubMed ID: 7493338
[TBL] [Abstract][Full Text] [Related]
32. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
33. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen.
Sharkey RM; Kaltovich FA; Shih LB; Fand I; Govelitz G; Goldenberg DM
Cancer Res; 1988 Jun; 48(11):3270-5. PubMed ID: 3365705
[TBL] [Abstract][Full Text] [Related]
34. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
35. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
[TBL] [Abstract][Full Text] [Related]
36. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
38. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization.
Casalini P; Luison E; Ménard S; Colnaghi MI; Paganelli G; Canevari S
J Nucl Med; 1997 Sep; 38(9):1378-81. PubMed ID: 9293791
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
40. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
